MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
July 22, 2024 08:10 ET
|
MiMedx Group, Inc
Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first...
MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
July 17, 2024 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second...
MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
June 26, 2024 16:01 ET
|
MiMedx Group, Inc
MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller...
MIMEDX to Participate in Upcoming Investor Conferences
May 15, 2024 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following...
MIMEDX Announces First Quarter 2024 Operating and Financial Results
April 30, 2024 16:01 ET
|
MiMedx Group, Inc
Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales ...
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
April 16, 2024 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first...
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
March 27, 2024 08:00 ET
|
MiMedx Group, Inc
Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the...
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
March 20, 2024 07:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain...
MIMEDX Introduces E-Commerce and Account Management Platform
March 13, 2024 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of MIMEDX Connect™, an online product ordering and account...
MIMEDX Announces Appointment of Two New Independent Directors
March 04, 2024 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of...